- Market Capitalization, $K 182,397
- Shares Outstanding, K 16,703
- Annual Sales, $ 0 K
- Annual Income, $ -25,910 K
- 60-Month Beta 0.20
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 44.38
|Period||Period Low||Period High||Performance|
| || |
-0.45 (-3.96%)since 08/28/20
| || |
+0.17 (+1.58%)since 06/26/20
| || |
+5.09 (+87.46%)since 09/27/19
Avenue Therapeutics, Inc. (NASDAQ: ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that a publication entitled "IV tramadol: A...
Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.
Avenue Therapeutics, Inc. (NASDAQ: ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today reported financial results and recent corporate highlights...
Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and...
Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.
Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.
Veru (VERU) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for June 24th
Applied Genetic (AGTC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.